Overview

A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.

Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
A Phase I, Open Label, Randomized, Two-way Crossover, Single Dose Study to Determine the Bioequivalence of Ethinylestradiol + Gestodene - The objective of the study is to verify through a single dose study, if the two formulations of Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets are bioequivalent when administered at the same dose and under fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Ethinyl Estradiol
Femovan
Gestodene